S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Mitigating Bioanalytical Risks Across Global Clinical Research Sites

As drug development programs expand globally, the demand for rigorous cross-validation of bioanalytical assays has intensified. Ensuring data consistency across multiple laboratories remains a critical hurdle for maintaining regulatory compliance and the integrity of pharmacokinetic, immunogenicity, and biomarker assessments in high-stakes clinical studies.

Mitigating Bioanalytical Risks Across Global Clinical Research Sites
Photo: Bio & News

Variability stemming from site-specific reagents, differing instrumentation, or analyst interpretation often threatens the comparability of bioanalytical results. To address these challenges, a team from BioAgilytix will host an upcoming webinar focused on standardizing assay transfer protocols. The session aims to provide actionable strategies for demonstrating assay concordance by utilizing reference standards and quality controls to mitigate site-to-site performance gaps.

Speakers including Lynn Kamen, Jessica Weaver, Pavan Prathipati, Bryan M. Gullick, Michael Mullen, and Todd Lester will detail fit-for-purpose statistical methodologies. The discussion will cover the practical application of equivalence testing and bias assessment to identify and characterize inter-site discordance. The event is scheduled for July 20, 2026, at 10am EDT, offering a deep dive into the technical frameworks required to satisfy evolving regulatory expectations in multi-site clinical trials.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!